Thursday, May 19, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

Researchers demonstrate how a narrow-spectrum antibiotic selectively targets C. diff

by Medical Finance
in News
New mathematical model can calculate the risk of resistance evolution for drug pairs
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Most antibiotics are double-edged swords. Besides killing the pathogen they are prescribed for, they also decimate beneficial bacteria and change the composition of the gut microbiome. As a result, patients become more prone to reinfection, and drug-resistant strains are more likely to emerge.

The answer to this problem might be narrow-spectrum antibiotics that kill only one or a few species of bacteria, minimizing the risk of collateral damage. In a recent study, Rockefeller scientists took a close look at one such antibiotic, fidaxomicin, used to treat Clostridium difficile, or C. diff, one of the most common healthcare associated infections. The researchers demonstrated at a molecular level how fidaxomicin selectively targets C. diff while sparing the innocent bacterial bystanders.

The findings, detailed in Nature, might help scientists in the race to develop new narrow-spectrum antibiotics against other pathogens.

I want people, scientists, and doctors to think differently about antibiotics. Since our microbiome is crucial to health, narrow-spectrum approaches have an important part to play in how we treat bacterial infections in the future.”


Elizabeth Campbell, research associate professor, Rockefeller University

Enigmatically selective

C. diff is a toxin-producing bacterium that can inflame the colon and cause severe diarrhea. It infects about half a million people in the United States, mostly in a hospital setting, and about one in 11 of those over age 65 who die within a month.

For years, doctors have used broad spectrum antibiotics to treat C. diff. Fidaxomicin is a relatively new alternative that was granted FDA approval in 2011.

Like several other antibiotics including the tuberculosis drug rifampicin, fidaxomicin targets an enzyme called the RNA polymerase (RNAP), which the bacterium uses to transcribe its DNA code into RNA. To understand exactly why fidaxomicin selectively inhibits RNAP in C. diff and not in most other bacteria, Campbell teamed up with biochemist Robert Landick from the University of Wisconsin-Madison to visualize C. diff RNAP using cryo-electron microscopy, a powerful imaging technique that can reveal the 3D shape of molecules, and capture the drug molecule and its target in action. “Although the overall architecture of RNAP in diverse bacteria is similar, there are still considerable differences,” Campbell says.

Spying on RNAP

One big challenge, however, was to first produce large amounts of C. diff, an anaerobic germ that doesn’t grow in the presence of oxygen. The study’s first author, Xinyun Cao, from the Landick Lab, spent two years developing a system to more easily produce C. diff RNAP using E. Coli, an easy growing bacterium frequently used in the lab.

Using this material, co-first author Hande Boyaci a postdoc on Campbell’s team generated images of C. diff RNAP locked with fidaxomicin at near-atomic resolution. Wedged into a hinge between two subunits of RNAP, fidaxomicin jams open the enzyme’s pincer, preventing it from grabbing on to genetic material and starting the transcription process.

In closely examining the points of contact between RNAP and fidaxomicin, the researchers identified one amino acid on the RNAP that binds to fidaxomicin but is absent in the main groups of gut microbes that are spared by fidaxomicin. A genetically altered version of C. diff that lacked this amino acid was unperturbed by fidaxomicin, just like other commensal bacteria in the gut. Conversely, bacteria that had it added to their RNAP became sensitive to fidaxomicin.

The findings suggest this one amino acid among the 4,000 amino acids of this robust and essential transcription machine is its Achilles heel, responsible for the killing of the bacteria by fidaxomicin.

The approach used in this study proposes a roadmap to developing new and safer antibiotics, the researchers say. By further elucidating RNAP structure of diverse bacteria, scientists can design antibiotics that targets each pathogen more selectively and effectively.

Source:

Journal reference:

Cao, X., et al. (2022) Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile. Nature. doi.org/10.1038/s41586-022-04545-z.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

‘Lefty’ protein pumps the brakes during initial stages of embryo differentiation

Using ‘off-the-shelf’ engineered stem cell based therapy for treating glioblastomas post-surgery

by Medical Finance
May 19, 2022
0

Glioblastomas (GBMs) are highly aggressive cancerous tumors of the brain and spinal cord. Brain cancers like GBM are challenging to...

First patient-derived stem cell model developed for studying oculocutaneous albinism

New stem cell model could help map out the key genomic changes during early development

by Medical Finance
May 19, 2022
0

Researchers from the Babraham Institute have today published their latest work in the journal Cell Stem Cell describing a new...

Study: An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Image Credit: picmedical / Shutterstock.com

Antibodies that neutralize most sarbecoviruses, including SARS-CoV-2 variants

by Medical Finance
May 19, 2022
0

As of April 21, 2022, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19),...

Salk scientists identify a protein that is critical for preventing pancreatic auto-digestion in mice

Salk scientists identify a protein that is critical for preventing pancreatic auto-digestion in mice

by Medical Finance
May 19, 2022
0

Every day, your pancreas produces about one cup of digestive juices, a mixture of molecules that can break down the...

Omicron variant found to be much less sensitive to neutralizing antibodies than Delta

Omicron variant found to be much less sensitive to neutralizing antibodies than Delta

by Medical Finance
May 19, 2022
0

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to...

Maternal transfer of healthier gut bacteria helps neonates to resist biliary atresia

Microbes can influence which of the gut’s genes are being called into action

by Medical Finance
May 19, 2022
0

The microbes that help break down food actually tell the gut how to do its job better, according to a...

Next Post
Study: SARS-CoV-2 Infections in Professional Orchestra and Choir Musicians – A Prospective Cohort Study. Image Credit: Skreidzeleu/Shutterstock

Incidence of SARS-CoV-2 infections in orchestra and choir musicians

Study: NRP1 and furin as putative mediators of SARS-CoV-2 entry into human brain cells. Image Credit: Kateryna Kon/Shutterstock

Researchers discover mechanism behind SARS-CoV-2 entry into the brain

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Insulin 620x480
    Researchers untangle the mysteries around type-2 diabetes
  • Study: Total infectome characterization of respiratory infections in pre-COVID-19 Wuhan, China. Image Credit: sleepingpanda/Shutterstock
    Pathogens in pneumonia-associated respiratory samples from Wuhan prior to SARS-CoV-2 emergence
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply